TIGAR = TP53-induced glycolysis and apoptosis regulator. AT = ataxia–telangiectasia; ATM = ataxia–telangiectasia mutated; bp = base pair; CDKN1A = cyclin-dependent kinase inhibitor 1 ...

"This is the first combination of a BTK inhibitor plus a BCL-2 inhibitor that ... such as a chromosome 17 deletion or a TP53 gene mutation, were specifically excluded from the trial because ...

Here we report a case of a T-cell lymphoma harboring a lentiviral integration in a known tumor suppressor, TP53, which developed in a patient with multiple myeloma after B-cell maturation antigen ...

Key mutations were observed in TP53 and ARID1A genes and TP53 pathway was downregulated in patients with primary treatment resistance. A high-risk signature based on the identified molecular ...

Defects in the DNA damage sensors, particularly in the ataxia telengiectasia mutated (ATM)/TP53 pathways ... CD52), cyclin-depenent kinase (CDK) inhibitors such as flavopiridol, and steroids.

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...